Nob Hill Therapeutics was selected as a finalist in the Redefining Early Stage Investments (RESI) Innovator’s Pitch Challenge (IPC). An opportunity for early-stage companies to gain exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. The IPC focuses on early-stage life science companies actively raising capital and is a valuable platform for startups and investors/strategic partners to connect and start a dialogue. The pitch sessions are live during the Digital RESI conference and include a Q&A by a curated panel of investor judges.
"Being invited to attend the pitch challenge by NIH/RESI is a validation/confirmation of our product and technology's innovation in drug delivery. Through participating in the event, NHT gained positive exposures. We are honored to be mentored by the NIH team of experts and be part of the event." said NHT CEO, Yun Li.
Nob Hill Therapeutics mission is to commercialize the first of its kind dry powder nebulizer (DryNeb) inhalation drug delivery platform. NHT focuses on creating effective inhalation therapies to address lower respiratory tract infections (the 5th leading overall cause of death worldwide) and other deadly lung diseases.
Learn more about NHT pitch session here: resiconference.com/pitch-challenge